Clinical Trial Update: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating navitoclax in combination with dabrafenib and trametinib for patients with BRAF-mutant melanoma; the study is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Navitoclax (navitoclax)
• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING